MTBP

Summary

MTBP (MDM2 binding protein, HGNC:7417) is a protein-coding gene on chromosome 8q24.12, encoding Mdm2-binding protein (Q96DY7). Inhibits cell migration in vitro and suppresses the invasive behavior of tumor cells. It is a common-essential gene (DepMap: required in 99.8% of cancer cell lines).

This gene encodes a protein that interacts with the oncoprotein mouse double minute 2. The encoded protein regulates progression through the cell cycle and may be involved in tumor formation.

Source: NCBI Gene 27085 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 127 total
• Cancer dependency (DepMap): dependent in 99.8% of screened cell lines (common-essential)
• MANE Select transcript: NM_022045

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7417
Approved symbol	MTBP
Name	MDM2 binding protein
Location	8q24.12
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000172167
Ensembl biotype	protein_coding
OMIM	605927
Entrez	27085

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 4 retained_intron, 3 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000305949, ENST00000456899, ENST00000519188, ENST00000519556, ENST00000519841, ENST00000522308, ENST00000522449, ENST00000523373, ENST00000936431, ENST00000936432

RefSeq mRNA: 1 — MANE Select: NM_022045 NM_022045

CCDS: CCDS6333

Canonical transcript exons

ENST00000305949 — 22 exons

Exon	Start	End
ENSE00001157795	120522654	120522719
ENSE00001157803	120518704	120518817
ENSE00001157809	120517851	120518100
ENSE00001157816	120515925	120516191
ENSE00001157822	120509934	120510029
ENSE00001157828	120506706	120506861
ENSE00001157832	120502492	120502609
ENSE00001157838	120497393	120497554
ENSE00001157843	120490463	120490570
ENSE00001157850	120488159	120488332
ENSE00001157865	120463692	120463761
ENSE00001157877	120459215	120459349
ENSE00001157885	120456553	120456670
ENSE00001157892	120455435	120455579
ENSE00001157903	120453847	120453905
ENSE00001157912	120451171	120451322
ENSE00001175780	120523298	120523636
ENSE00001175789	120445419	120445588
ENSE00003554500	120451003	120451076
ENSE00003594089	120461161	120461255
ENSE00003595841	120446433	120446513
ENSE00003617751	120470820	120470937

Expression profiles

Bgee: expression breadth ubiquitous, 163 present calls, max score 82.91.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.6548 / max 96.9110, expressed in 1350 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
90424	5.2821	1333
90425	0.3727	208

Top tissues by expression

241 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.91	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	81.80	gold quality
ventricular zone	UBERON:0003053	80.84	gold quality
buccal mucosa cell	CL:0002336	79.14	silver quality
cerebellar hemisphere	UBERON:0002245	79.14	gold quality
cerebellar cortex	UBERON:0002129	79.10	gold quality
calcaneal tendon	UBERON:0003701	78.88	gold quality
right hemisphere of cerebellum	UBERON:0014890	78.25	gold quality
cerebellum	UBERON:0002037	77.16	gold quality
embryo	UBERON:0000922	76.99	gold quality
ganglionic eminence	UBERON:0004023	76.99	gold quality
adrenal tissue	UBERON:0018303	76.41	gold quality
sural nerve	UBERON:0015488	75.00	gold quality
stromal cell of endometrium	CL:0002255	74.89	gold quality
secondary oocyte	CL:0000655	72.03	gold quality
smooth muscle tissue	UBERON:0001135	71.83	gold quality
rectum	UBERON:0001052	71.78	gold quality
bone marrow cell	CL:0002092	71.00	gold quality
vermiform appendix	UBERON:0001154	70.64	gold quality
monocyte	CL:0000576	70.16	gold quality
leukocyte	CL:0000738	69.93	gold quality
lymph node	UBERON:0000029	69.38	gold quality
islet of Langerhans	UBERON:0000006	69.33	gold quality
tibial nerve	UBERON:0001323	68.95	gold quality
right testis	UBERON:0004534	68.88	gold quality
Brodmann (1909) area 9	UBERON:0013540	68.60	gold quality
right ovary	UBERON:0002118	68.34	gold quality
body of uterus	UBERON:0009853	68.23	gold quality
left ovary	UBERON:0002119	68.20	gold quality
testis	UBERON:0000473	68.09	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.51
E-MTAB-6379	no	192.33

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

23 targeting MTBP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-1284	99.67	73.56	1353
HSA-MIR-26A-1-3P	99.64	66.81	788
HSA-MIR-26A-2-3P	99.64	66.82	786
HSA-MIR-802	99.61	67.70	1254
HSA-MIR-6073	99.60	70.36	793
HSA-MIR-1276	99.36	68.18	1642
HSA-MIR-4652-3P	99.33	70.02	2742
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-2054	99.20	68.89	1699
HSA-MIR-5701	98.97	69.54	1502
HSA-MIR-6074	98.89	69.64	2187
HSA-MIR-550A-3P	98.37	69.61	632
HSA-MIR-4778-5P	97.96	68.06	1634

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.8% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 12)

• identification and characterization of mouse Mdm2 binding protein (PMID:10906133)
• Data suggest that MTBP differentially regulates the activity of MDM2 towards two of its most critical targets (itself and p53) and in doing so significantly contributes to MDM2-dependent p53 homeostasis in unstressed cells. (PMID:15632057)
• MTBP contributes to MDM2 activity and through this to negative regulation of p53 (PMID:15632057)
• MTBP has an important role in recruiting and/or retaining the Mad1/Mad2 complex at the kinetochores during prometaphase, but its degradation is required for silencing the mitotic checkpoint. (PMID:21274008)
• results represent the first examination of MTBP expression in human tissues and provide evidence for a p53 status-dependent role for MTBP in suppressing disease progression in squamous cell carcinoma of the head and neck patients (PMID:21692053)
• MTBP also inhibited ACTN4-mediated F-actin bundling. (PMID:22370640)
• MTBP acts with Treslin/TICRR to integrate signals from cell cycle and DNA damage response pathways to control the initiation of DNA replication in human cells. (PMID:23704573)
• MTBP associated with MYC at promoters and increased MYC-mediated transcription, proliferation, neoplastic transformation, and tumor development. (PMID:24786788)
• MTBP significantly contributes to breast cancer survival and is a potential novel therapeutic target in Triple-negative breast cancer . (PMID:24866769)
• Overexpression of MTBP resulted in the suppression of the migratory and metastatic potential of Hepatocellular carcinoma cells, while its downregulation increased the migration. (PMID:25759210)
• data show that MTBP aggravates the invasion and metastasis of HCC by promoting the MDM2-mediated degradation of E-cadherin. (PMID:26280083)
• Binding of the Treslin-MTBP Complex to Specific Regions of the Human Genome Promotes the Initiation of DNA Replication. (PMID:32966791)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mtbp	ENSDARG00000090447
mus_musculus	Mtbp	ENSMUSG00000022369
rattus_norvegicus	Mtbp	ENSRNOG00000004412

Protein

Protein identifiers

Mdm2-binding protein — Q96DY7 (reviewed: Q96DY7)

All UniProt accessions (2): Q96DY7, H0YB28

UniProt curated annotations — full annotation on UniProt →

Function. Inhibits cell migration in vitro and suppresses the invasive behavior of tumor cells. May play a role in MDM2-dependent p53/TP53 homeostasis in unstressed cells. Inhibits autoubiquitination of MDM2, thereby enhancing MDM2 stability. This promotes MDM2-mediated ubiquitination of p53/TP53 and its subsequent degradation.

Subunit / interactions. Interacts with MDM2.

Similarity. Belongs to the MTBP family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96DY7-1	1	yes
Q96DY7-3	2

RefSeq proteins (1): NP_071328* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029418	MTBP_C	Domain
IPR029420	MTBP_central	Domain
IPR029421	MTBP_N	Domain
IPR039061	MTBP	Family

Pfam: PF14918, PF14919, PF14920

UniProt features (12 total): region of interest 4, modified residue 4, splice variant 2, chain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96DY7-F1	63.87	0.09

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 597, 639, 703, 707

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9766229	Degradation of CDH1

MSigDB gene sets: 173 (showing top): GOBP_REGULATION_OF_NUCLEAR_DIVISION, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_POSITIVE_REGULATION_OF_MITOTIC_CELL_CYCLE, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, AAAYRNCTG_UNKNOWN, GOBP_POSITIVE_REGULATION_OF_G1_S_TRANSITION_OF_MITOTIC_CELL_CYCLE, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS, GOBP_ORGANELLE_FISSION, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_PROTEIN_LOCALIZATION_TO_CHROMOSOME_CENTROMERIC_REGION, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE, GOBP_PROTEIN_LOCALIZATION_TO_CHROMOSOME, GOBP_REGULATION_OF_CELL_CYCLE

GO Biological Process (6): traversing start control point of mitotic cell cycle (GO:0007089), negative regulation of cell population proliferation (GO:0008285), regulation of protein ubiquitination (GO:0031396), protein localization to kinetochore (GO:0034501), negative regulation of mitotic nuclear division (GO:0045839), regulation of cell cycle (GO:0051726)

GO Molecular Function (0):

GO Cellular Component (2): kinetochore (GO:0000776), chromatin (GO:0000785)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Regulation of CDH1 Function	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of G1/S transition of mitotic cell cycle	1
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
protein ubiquitination	1
regulation of protein modification by small protein conjugation or removal	1
protein localization to chromosome, centromeric region	1
protein localization to condensed chromosome	1
regulation of mitotic nuclear division	1
negative regulation of cell cycle process	1
negative regulation of mitotic cell cycle	1
negative regulation of nuclear division	1
mitotic nuclear division	1
cell cycle	1
regulation of cellular process	1
condensed chromosome, centromeric region	1
intracellular membraneless organelle	1
supramolecular complex	1
chromosome	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1338 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MTBP	TICRR	Q7Z2Z1	964
MTBP	MDM2	Q00987	880
MTBP	RECQL4	O94761	719
MTBP	TOPBP1	Q92547	676
MTBP	TBP	P20226	593
MTBP	CDC45	O75419	573
MTBP	DHCR24	Q15392	560
MTBP	TP53	P04637	555
MTBP	MYC	P01106	551
MTBP	PSMA3	P25788	548
MTBP	MDM4	O15151	520
MTBP	TCHP	Q9BT92	518
MTBP	DBF4	Q9UBU7	517
MTBP	AIRIM	Q9NX04	472
MTBP	RPL11	P25121	462

IntAct

19 interactions, top by confidence:

A	B	Type	Score
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
CDK19	MED19	psi-mi:“MI:0914”(association)	0.770
ZEB2	MTA2	psi-mi:“MI:0914”(association)	0.580
YWHAZ	BLTP3B	psi-mi:“MI:0914”(association)	0.530
CDK8	CCNC	psi-mi:“MI:0914”(association)	0.350
CCNA2	TBC1D4	psi-mi:“MI:0914”(association)	0.350
FKBP5	IFT56	psi-mi:“MI:0914”(association)	0.350
H2BC21	SMCHD1	psi-mi:“MI:0914”(association)	0.350
MIF	BLTP3B	psi-mi:“MI:0914”(association)	0.350
YWHAB	BRAF	psi-mi:“MI:0914”(association)	0.350
YWHAE	DEPDC5	psi-mi:“MI:0914”(association)	0.350
YWHAG	BRAF	psi-mi:“MI:0914”(association)	0.350
YWHAH	BRAF	psi-mi:“MI:0914”(association)	0.350
S100A2	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
AFG2A	ESYT2	psi-mi:“MI:0914”(association)	0.350
AFG2B	MMP24OS	psi-mi:“MI:0914”(association)	0.350
	MTBP	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (60): MTBP (Affinity Capture-MS), MTBP (Biochemical Activity), MTBP (Affinity Capture-MS), MTBP (Affinity Capture-MS), MTBP (Affinity Capture-MS), MTBP (Positive Genetic), MTBP (Positive Genetic), MTBP (Negative Genetic), MTBP (Negative Genetic), MTBP (Negative Genetic), MTBP (Positive Genetic), MTBP (Negative Genetic), MTBP (Negative Genetic), MTBP (Positive Genetic), NDUFB1 (Negative Genetic)

ESM2 similar proteins: A0JMD2, A1L2H3, A2AKX3, A5WUT8, A5WWB6, A6NKB5, B0S6S9, D3Z987, E1BC15, F1MF21, O36397, O60673, O77797, P97412, Q0P4S0, Q15468, Q28DZ0, Q3MHH3, Q3MJ40, Q3V089, Q49AJ0, Q4V7H1, Q4V7J0, Q5CZC0, Q5DTT3, Q5SWW4, Q5VWN6, Q5ZKL9, Q60988, Q61493, Q641I1, Q66HB6, Q6IRT3, Q6NS59, Q6ZP01, Q7Z333, Q80TA9, Q80U59, Q8BJS8, Q92628

Diamond homologs: Q0P4G8, Q6NRW0, Q8BJS8, Q96DY7

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 27 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	6	183.2×	9e-11
Activation of BAD and translocation to mitochondria	5	173.0×	5e-09
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	5	152.7×	8e-09
Activation of BH3-only proteins	5	112.8×	3e-08
RHO GTPases activate PKNs	5	72.1×	2e-07
Intrinsic Pathway for Apoptosis	5	66.5×	3e-07
Translocation of SLC2A4 (GLUT4) to the plasma membrane	6	42.1×	2e-07
Transcriptional and post-translational regulation of MITF-M expression and activity	5	40.5×	2e-06

GO biological processes:

GO term	Partners	Fold	FDR
intracellular protein localization	5	20.1×	6e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

127 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	96
Likely benign	5
Benign	7

Top pathogenic / likely-pathogenic (0)

SpliceAI

4543 predictions. Top by Δscore:

Variant	Effect	Δscore
8:120446428:TTCA:T	acceptor_loss	1.0000
8:120446429:TCAG:T	acceptor_loss	1.0000
8:120446430:CA:C	acceptor_loss	1.0000
8:120446431:A:AG	acceptor_gain	1.0000
8:120446432:G:GA	acceptor_gain	1.0000
8:120446432:GA:G	acceptor_gain	1.0000
8:120446432:GAC:G	acceptor_gain	1.0000
8:120446432:GACT:G	acceptor_gain	1.0000
8:120446432:GACTT:G	acceptor_gain	1.0000
8:120446509:CCCTG:C	donor_gain	1.0000
8:120446510:CCTG:C	donor_gain	1.0000
8:120446511:CTG:C	donor_gain	1.0000
8:120446511:CTGGT:C	donor_loss	1.0000
8:120446512:TG:T	donor_gain	1.0000
8:120446512:TGGTA:T	donor_loss	1.0000
8:120446513:GG:G	donor_gain	1.0000
8:120446513:GGTA:G	donor_loss	1.0000
8:120446514:G:GG	donor_gain	1.0000
8:120446514:GTA:G	donor_loss	1.0000
8:120446515:TAAG:T	donor_loss	1.0000
8:120451000:A:AG	acceptor_gain	1.0000
8:120451001:A:G	acceptor_gain	1.0000
8:120451002:G:GG	acceptor_gain	1.0000
8:120451002:GCCT:G	acceptor_gain	1.0000
8:120451169:A:AG	acceptor_gain	1.0000
8:120451170:G:GG	acceptor_gain	1.0000
8:120451170:GTTTT:G	acceptor_gain	1.0000
8:120451288:GACA:G	donor_gain	1.0000
8:120451292:G:GG	donor_gain	1.0000
8:120451302:G:GT	donor_gain	1.0000

AlphaMissense

5923 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:120518720:T:A	V838D	0.995
8:120456638:T:A	W239R	0.994
8:120456638:T:C	W239R	0.994
8:120518813:T:C	L869P	0.994
8:120522688:T:C	M882T	0.994
8:120470898:T:A	W376R	0.993
8:120470898:T:C	W376R	0.993
8:120518789:T:C	L861P	0.993
8:120506807:T:C	F610S	0.992
8:120518708:T:C	L834P	0.992
8:120518786:G:C	R860P	0.991
8:120451186:T:A	W97R	0.990
8:120451186:T:C	W97R	0.990
8:120518732:T:C	L842P	0.990
8:120518099:G:C	R832P	0.989
8:120506806:T:C	F610L	0.988
8:120506808:T:A	F610L	0.988
8:120506808:T:G	F610L	0.988
8:120522658:T:C	L872P	0.988
8:120518092:C:G	H830D	0.985
8:120518776:T:C	C857R	0.985
8:120518789:T:A	L861H	0.985
8:120518082:A:C	R826S	0.983
8:120518082:A:T	R826S	0.983
8:120518785:C:A	R860S	0.983
8:120522688:T:G	M882R	0.983
8:120522689:G:A	M882I	0.983
8:120522689:G:C	M882I	0.983
8:120522689:G:T	M882I	0.983
8:120451048:C:A	A82E	0.982

dbSNP variants (sampled 300 via entrez): RS1000057682 (8:120502398 C>A,G,T), RS1000082843 (8:120483270 C>G,T), RS1000109635 (8:120501800 A>T), RS1000133911 (8:120468312 C>T), RS1000193835 (8:120508623 A>G), RS1000264378 (8:120458356 T>C), RS1000274660 (8:120457597 A>G), RS1000303110 (8:120514959 G>A), RS1000332997 (8:120471326 A>G), RS1000364673 (8:120521385 C>T), RS1000382421 (8:120508916 C>A), RS1000513872 (8:120469025 T>G), RS1000538086 (8:120482988 C>T), RS1000581532 (8:120488001 C>A), RS1000609893 (8:120508215 C>G)

Disease associations

OMIM: gene MIM:605927 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST004070_21	Cerebrospinal P-tau181p levels	7.000000e-06
GCST004071_14	Cerebrospinal T-tau levels	4.000000e-06
GCST009391_1798	Metabolite levels	8.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004763	p-tau measurement
EFO:0004760	t-tau measurement
EFO:0010449	3-methyladipic acid measurement
EFO:0010524	pimelic acid measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	5
bisphenol A	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
butyraldehyde	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
incobotulinumtoxinA	decreases expression	1
(+)-JQ1 compound	decreases expression	1
Dasatinib	decreases expression	1
Sunitinib	decreases expression	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Benzo(a)pyrene	increases expression	1
Caffeine	decreases phosphorylation	1
Calcitriol	affects cotreatment, decreases expression	1
Cisplatin	decreases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Dinitrochlorobenzene	affects binding	1
Methyl Methanesulfonate	increases expression	1
Testosterone	affects cotreatment, decreases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer